Kymera Investor Presentation Deck

KT-253: Phase 1, Multicenter, Dose-Escalation and Expansion Trial to Evaluate KT-333 in Adult Patients with Liquid and Solid Tumors Hematological Malignancies ● AML identified as initial indication based on strong pre-clinical KT-253 activity Developed patient stratification strategy to target subsets of leukemias most sensitive to KT-253 as mono- and combination therapy Preclinical data also support potential development in other heme indications, such as ALL and P53WT lymphomas Solid Tumors Preclinical studies have identified several solid tumor types sensitive to KT-253 DLX KYMERA ©2023 KYMERA THERAPEUTICS, INC. DLx+1 Pharmacologically Active Dose in ST/L Solid Tumors/Lymphoma Phase 1a Phase 1b DLx+2 DLy Phase 1a DLY+1 DLn R/R high-grade Myeloid Malignancies/ALL DL₁ DLY +2 Key Objectives Primary Secondary Exploratory MTD/RP2D ● MTD/RP2D Phase 1a Safety, MED and/or RP2D PK Preliminary Efficacy PD . Phase 1b Solid Tumor TBD n=20 Lymphoma TBD n=20 R/RAML P53WT R/R AML n = 20 Phase 1b Safety at MED/ RP2D (AML) Preliminary Efficacy PK PD Initiate dose escalation in solid tumor/lymphoma (ST/L) Initiate dose escalation in AML once pharmacologically active dose identified in ST/L Initiate expansion in R/R AML Initiate expansions in select solid tumors and lymphomas based on data from 1a and ongoing preclinical efforts PAGE 57

View entire presentation